{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:13:38Z","timestamp":1761498818449,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beha.2023.101442","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:27:49Z","timestamp":1675348069000},"page":"101442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma"],"prefix":"10.1016","volume":"36","author":[{"given":"Yaya","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliza","family":"Gardenswartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianna J.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/bjh.15764","article-title":"Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives","volume":"185","author":"Cairo","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib2","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/bjh.15753","article-title":"Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma","volume":"185","author":"Chu","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.15491","article-title":"Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB\/LMB 96: a report from the FAB\/LMB 96 study group","volume":"182","author":"Cairo","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.beha.2023.101442_bib4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2023.101442_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children's Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.beha.2023.101442_bib6","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/s41375-021-01256-8","article-title":"A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma","volume":"35","author":"Goldman","year":"2021","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.beha.2023.101442_bib7","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.beha.2023.101442_bib8","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.18632\/oncotarget.27691","volume":"11","author":"Chu","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2023.101442_bib10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101442_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040802","article-title":"The many facets of CD38 in lymphoma: from tumor-microenvironment cell interactions to acquired resistance to immunotherapy","volume":"9","author":"Calabretta","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.beha.2023.101442_bib12","first-page":"995","volume":"1","author":"Bride","year":"2018"},{"volume":"1","year":"2022","author":"Vakrmanova","key":"10.1016\/j.beha.2023.101442_bib13"},{"key":"10.1016\/j.beha.2023.101442_bib14","first-page":"713","volume":"1","author":"Vogiatzi","year":"2019"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000630","volume":"8","author":"Tembhare","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"16_suppl","key":"10.1016\/j.beha.2023.101442_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101442_bib17","first-page":"293","volume":"1","author":"Ofran","year":"2020"},{"issue":"5","key":"10.1016\/j.beha.2023.101442_bib18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/cam4.4478","article-title":"Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: phase 2 study","volume":"11","author":"Boissel","year":"2022","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.beha.2023.101442_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2018.12.013","article-title":"Phase 2 study of daratumumab in relapsed\/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma","volume":"19","author":"Salles","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib21","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: possible biomarkers for novel targeted therapies?","volume":"92","author":"Zaja","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2023.101442_bib22","first-page":"25","volume":"1","author":"Huang","year":"2021"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101442_bib24","series-title":"Reducing chemoradiotherapy and radiation exposure from diagnostic imaging by utilizing targeted immunotherapy in children, adolescents and young adults (CAYA) with mature large B-cell lymphoma (RADICAL)","first-page":"S40","author":"Audino","year":"2022"},{"key":"10.1016\/j.beha.2023.101442_bib25","series-title":"Safety and tolerability of myeloablative conditioning and autologous stem cell transplantation followed by polatuzumab vedotin (PV) immnoconjugate therapy inpatients with B-cell non-hodgkin lymphoma","first-page":"S24","author":"Gardenswartz","year":"2022"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evidence"},{"issue":"12","key":"10.1016\/j.beha.2023.101442_bib27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2023.101442_bib28","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: children's Oncology group protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2023.101442_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2023.101442_bib30","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.beha.2023.101442_bib31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10306","key":"10.1016\/j.beha.2023.101442_bib32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2023.101442_bib33","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.beha.2023.101442_bib34","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.beha.2023.101442_bib35","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2023.101442_bib36","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10168","key":"10.1016\/j.beha.2023.101442_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2023.101442_bib38","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.beha.2023.101442_bib39","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J Clin Oncol"},{"year":"2021","series-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ALCL: results of COG trial ANHL12P1. Blood","author":"Lowe","key":"10.1016\/j.beha.2023.101442_bib40"},{"issue":"26","key":"10.1016\/j.beha.2023.101442_bib41","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.beha.2023.101442_bib43","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.beha.2023.101442_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.beha.2023.101442_bib46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.beha.2023.101442_bib47","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.beha.2023.101442_bib49","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2023.101442_bib50","first-page":"JCO2102370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101442_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood-2021-148473","article-title":"Long-term follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (iNHL)","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101442_bib52","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101442_bib53","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2023.101442_bib54","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.beha.2023.101442_bib55","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.beha.2023.101442_bib56","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101442_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.beha.2023.101442_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1341031","article-title":"M SC. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.beha.2023.101442_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101442_bib61","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2019-129319","article-title":"FT596: translation of first-of-kind multi-antigen targeted off-the-shelf CAR-NK cell with engineered persistence for the treatment of B cell malignancies","volume":"134","author":"Goodridge","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib62","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Naeimi Kararoudi","year":"2022","journal-title":"Cell Rep Methods"},{"issue":"4","key":"10.1016\/j.beha.2023.101442_bib63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminhematol.2020.11.006","article-title":"Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity","volume":"57","author":"Naeimi Kararoudi","year":"2020","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.beha.2023.101442_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Steel","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.beha.2023.101442_bib65","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.beha.2023.101442_bib66","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","article-title":"Novel human interleukin-15 agonists","volume":"183","author":"Zhu","year":"2009","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.beha.2023.101442_bib67","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","article-title":"Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma","volume":"27","author":"Foltz","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"46","key":"10.1016\/j.beha.2023.101442_bib68","doi-asserted-by":"crossref","first-page":"23869","DOI":"10.1074\/jbc.M116.733600","article-title":"A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses","volume":"291","author":"Liu","year":"2016","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2023.101442_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001238","article-title":"Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma","volume":"8","author":"Chu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2023.101442_bib70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.01.013","article-title":"ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children","volume":"110","author":"Pearson","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beha.2023.101442_bib71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"10.1016\/j.beha.2023.101442_bib72","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.beha.2023.101442_bib73","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.beha.2023.101442_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fonc.2019.00051","article-title":"Overcoming resistance to natural killer cell based immunotherapies for solid tumors","volume":"9","author":"Nayyar","year":"2019","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.beha.2023.101442_bib75","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.2020009806","article-title":"Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1","volume":"137","author":"Lowe","year":"2021","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:47Z","timestamp":1761498467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521692623000038"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101442","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101442"}}